SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001640455-21-000141
Filing Date
2021-11-04
Accepted
2021-11-04 07:12:45
Documents
14
Period of Report
2021-11-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K jnce-20211104.htm   iXBRL 8-K 39798
2 EX-99.1 jnce09302021exhibit991.htm EX-99.1 69170
6 jounceheadera.jpg GRAPHIC 45197
  Complete submission text file 0001640455-21-000141.txt   322577

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT jnce-20211104.xsd EX-101.SCH 1903
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT jnce-20211104_lab.xml EX-101.LAB 24831
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT jnce-20211104_pre.xml EX-101.PRE 13047
7 EXTRACTED XBRL INSTANCE DOCUMENT jnce-20211104_htm.xml XML 11639
Mailing Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139 857-259-3840
Jounce Therapeutics, Inc. (Filer) CIK: 0001640455 (see all company filings)

IRS No.: 454870634 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37998 | Film No.: 211377978
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences